This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The biopharma company will be required to seek prior approval before acquiring related products. to address the potential competitive harm Amgen’s $27.8 We believe the government can protect competition while enhancing the value of biotech M&A activity,” John Delacourt, Deputy General Counsel for BIO declared.
Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56
According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 percent from $3.45 trillion in Q2 2022 to $3.14 trillion in Q3 2022. percent and 16.2
Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market. The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff.
Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.
Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
The complaint alleges multiple violations of the Valentine Act, Ohio’s antitrust law, which prohibits price fixing, controlled sales and other agreements that restrain trade and hurt competition.
June 27, 2022 The payout curve against which a sales force is compensated has tremendous ability to motivate the sales force to drive sales—so much so that we are dedicating a three-part series to biopharma payout curve design. PAYOUT THRESHOLD Start very early to immediately engage the sales force.
The severity and impact of the Omicron variant is still being assessed, forcing biopharma companies to grapple with immense uncertainty during one of the most important planning periods of the year, including 2022 sales incentive compensation planning. TERRITORY-LEVEL CONTINGENCY PLAN. 100%/80%) in order to make the territory whole.
Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. How can we maximise marketing, sales, medical, access, and other teams’ efforts while making their jobs easier? Truly understanding the competitive landscape and market environment.
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Despite a drop in sales from Regeneron’s COVID-19 antibody, REGEN-COV, due to ineffectiveness against the Omicron variant, the company experienced record US sales of $1.63 trillion in Q2 2022 to $3.14
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Mirati has declined to comment on the speculation.
European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.
The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 The company’s blockbuster immunotherapy oncology drug, Keytruda, a monoclonal antibody that targets PD-1, continues to reap record sales with an analyst consensus global sales forecast of $20.8 trillion to $3.61 to $365.84.
According to Laursen, the decision to break into speciality enzymes was based on a look into the future of the biopharma market and an important assessment of how the company believes it can make a genuine difference. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry.
Nevertheless, launching a rare disease product continues to be incredibly challenging; in extreme cases, companies have even chosen to cease all commercial sales efforts for their rare disease treatment. However, patients may see several physicians before being diagnosed, meaning a small sales force may need to service many physicians.
In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans. Bridging this increasingly growing divide is not easy and raises the question of what truly makes a sales compensation plan simple. ATTRIBUTE 2 Simple to administer. Simple to understand. Simple to administer.
The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. ” The new data could accelerate partnering efforts of the drug this year.
July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. Why Don’t Sales Representatives Follow Call Plans? Why Don’t Sales Representatives Follow Call Plans?
March 9, 2021 Critical to optimizing sales force productivity and efficiency is identifying the right HCP and/or account targets. However, in the complex pharma, biotech and medical device landscape, the easy way of targeting HCPs is, unfortunately, not the right way in most circumstances, and ultimately diminishes sales and adoption.
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
November 13, 2023 Two critical elements that inform how biopharmasales representatives sell to HCPs are (1) the prescribing behavior exhibited by the HCP, or behavioral segment , and (2) the HCP’s loyalty to the products they prescribe. Consider a dominant single prescriber. make the prescriber become a dominant dual prescriber).
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.
Sales in the small molecule innovator CDMO market is expected to grow at a compound annual growth rate (CAGR) of 6.4 Accelerating advancement of research and technology in biopharma are generating opportunities for the industry to develop innovative small molecule drugs. billion in 2023 and $89.43 billion in 2033.
I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Now, due to the highly competitive environment, the process is truncated to 12-18 months.
Is it the secret to harmonizing pharma marketing and sales? Omnichannel strategies dont just enhance HCP experiences, they empower sales teams, too. This synergy has deepened the connection between Sales and Marketing in the Life Sciences industry, with HCPs at the center.
The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.
Companies need to carefully assess the value of the assets being acquired or licensed, considering factors such as the stage of development, market potential, the competitive landscape and intellectual property protection.
For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.
There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” Bates continued: “We expected a fall in investment following two bumper years, but it should still be considered a warning.
You are going to see a dramatic change in leadership’s urgency to leverage AI This new creative AI era will fuel massive advances in personalized customer service, drive new business models, improve real-time modeling ( Southwest Airlines ) and pave the way for breakthroughs in healthcare and biopharma from Google ‘s DeepMind.
forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.
exclusions exist for orphan drug designation and biosimilar competition ). Under buy and bill (B&B) in Medicare Part B, physician practices profit from reimbursement (historically Average Sales Price + 6% before sequestration) as well as rebates and discounts negotiated with manufacturers for hitting volume levels.
As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
The US still dominates the biopharma sector with more than $378bn in annual drug sales and an approximate capacity of 30% of global manufacturing. Hamilton offers more competitive prices than Toronto and the city is only an hour away from its larger neighbour. City Competitiveness Index. ft2 in Toronto 1.
With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. The arrival of a second drug may drive PBMs to expand coverage in exchange for aggressive rebates.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content